Drug Eluting Stent Market Size To Reach $6.7 Billion By 2033

Drug Eluting Stent Market Growth & Trends

The global drug eluting stent market size is expected to reach USD 6.7 billion by 2033, registering a CAGR of 6.7% from 2026 to 2033, according to a new report by Grand View Research, Inc. An aging population and the increasing prevalence of risk factors such as cardiovascular diseases (CVDs), complex lesions, diabetes, obesity, and others are expected to drive the demand for drug eluting stents over the forecast period. Additionally, ongoing technological advancements in stent design, including improvements in coatings and drug delivery mechanisms, are enhancing the safety and efficacy of these devices, making them more appealing to patients and healthcare professionals.

The increasing prevalence of cardiovascular diseases globally has fueled market demand. According to the World Health Federation report in 2022, over half a billion people globally continue to be affected by cardiovascular diseases, with CVD contributing to approximately 20.5 million deaths in 2021, accounting for nearly a third of all deaths globally. Conditions like coronary artery disease and peripheral artery disease are becoming increasingly common, leading to a surge in demand for effective treatment options such as DES. These stents, equipped with drug-coated surfaces, offer patients a minimally invasive solution, effectively preventing restenosis and leading to improved patient outcomes.

The market for drug eluting stents was significantly impacted by the COVID-19 pandemic, with disruptions in the supply chain of medical devices. Since the focus of all major manufacturers was to fight the COVID-19 battle, the revenues of other segments were highly impacted. All notable competitors in the market for coronary stents announced a decline in revenue for their interventional cardiology portfolios, which include coronary stent devices in 2020, owing mostly to the impact of the COVID-19 pandemic.

 Request a free sample copy or view report summary: Drug Eluting Stent Market Report

Drug Eluting Stent Market Report Highlights

• For instance, in January 2025, BIOTRONIK revealed expanded indications in Europe for its Orsiro Mission drug eluting stent, including use with 1-month DAPT and treatment of complex calcified lesions, highlighting advancements toward safer and more flexible patient-specific coronary interventions

• For instance, in July 2025, Teleflex Incorporated acquired the Vascular Intervention business of BIOTRONIK SE & Co. KG, including the Orsiro Mission drug eluting stent portfolio.

• For instance, in October 2025, MicroPort Scientific Corporation announced that its coronary stent portfolio, including the Firehawk drug eluting stent, has expanded to over 90 countries and 3,000+ hospitals worldwide, reflecting significant penetration in emerging and developed markets.

• The polymer-based coating segment accounted for the largest revenue share of over 82.8% in 2025, driven by its ability to provide controlled and sustained drug release, thereby significantly reducing restenosis rates and improving long-term clinical outcomes in percutaneous coronary interventions.

• By end use, the hospitals segment accounted for the largest revenue share of 68.3% in 2025, driven by the high volume of percutaneous coronary intervention (PCI) procedures performed in hospital settings.

• The North America drug eluting stents industry dominated with a share of 44.1% in 2025. Rising CVD cases, advanced healthcare infrastructure, and high awareness of interventional cardiology treatments, which support the widespread adoption of DES across hospitals and outpatient settings, fuel market growth.

Drug Eluting Stent Market Segmentation

Grand View Research has segmented the global drug eluting stents market report based on type of coating, end use, and region:

Drug Eluting Stent Type of Coating Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Polymer-based Coating

  • Non-biodegradable Polymers

  • Biodegradable Polymers

• Polymer-free Coating

  • Micro porous Surface

  • Micro structured Surface

  • Slotted tubular Surface

  • Nanoporous Surface

Drug Eluting Stent End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Hospitals

• Specialty Cardiac/Vascular Centers

• Ambulatory Surgical Centers (ASCs) 

Drug Eluting Stent Regional Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

  • Indonesia

  • Malaysia

  • Vietnam

• Latin America

  • Brazil

  • Argentina

  • Colombia

  • Chile

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Drug Eluting Stent Market

• Boston Scientific Corporation

• Medtronic

• Abbott

• Teleflex Incorporated (BIOTRONIK)

• Terumo Corporation

• B. Braun SE

• Translumina

• MicroPort Scientific Corporation

• Biosensors International Group, Ltd

• Lepu Medical

• iVascular S.L.U.

• SMT

• Meril Life Sciences Pvt. Ltd.

• Concept Medical

• Cardionovum GmbH